Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002895 (sickle cell disease)
 11,747 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The possible effect of pentoxifylline (Trental) in sickle celle disease was tested in 2 clinical trials: a controlled double-blinded intravenous study involving patients hospitalized with painful crises and an ublinded 5-month oral study in steady state patients. In the intravenous trial 29 painful episodes were treated in 16 patients. Complete blood counts, serum chemistries, red cell density gradients, intracellular pH, p50, whole blood viscosity, plasma viscosity and red cell distribution widths were monitored daily during the hospital admission. We confirmed the decrease of dense red cells during crisis and found, in addition, the related significant decrease in whole blood p50. There were no major differences in any of these parameters when pentoxifylline was compared to placebo for each individual day. When the data was examined over time, minor differences emerged. The red cell distribution width, the number of cells in density fraction SS2 (discocytes) and the plasma viscosity were all slightly higher over time in the pentoxifylline group than in the control group. In the oral group 23 patients were monitored for the same parameters on seven visits during a five month period. Administration of oral pentoxifylline produced no changes from baseline for all parameters examined except for a statistically significant, but minor, increase in plasma viscosity demonstrable for these patients during one visit only. We conclude that pentoxifylline has little effect on laboratory parameters in sickle cell disease.
 ...
PMID:Pentoxifylline (Trental) has no significant effect on laboratory parameters in sickle cell disease. 269 97

Erythrocytes from 14 patients with homozygous sickle cell anaemia were treated with the calcium ionophore A23187 to induce loss of cellular potassium and water. The dehydrated cells showed a decrease in filterability (loss of deformability) through pores of 5 micron diameter. Oxpentifylline and cetiedil citrate, which preserve erythrocyte cation and water content, had a significant (p less than 0.01) protective effect against loss of deformability at a concentration of 1 mumol/l. Oxpentifylline showed no adverse effect on the rheology, morphology, or haemolysis of sickle cells at concentrations up to 500 mumol/l. Drugs that act on the erythrocyte membrane to maintain cell hydration are of potential rheological benefit in sickle cell anaemia.
 ...
PMID:Oxpentifylline and cetiedil citrate improve deformability of dehydrated sickle cells. 311 75

Sixty patients (37 males, 23 females, age range 7 to 34 years) suffering from sickle cell disease were treated with pentoxifylline (1200 mg/day per os, Trental 400 t.i.d.) or placebo in a double-blind randomized study of six week duration. Observation of pain frequency, intensity and duration of pain events as well as determination of various laboratory and hematologic parameters were maintained on weekly or biweekly basis, respectively, throughout the study. At the end of the trial the number of patients (14) with pain periods and the number of pain events (57) and the mean duration of pain events (4.1 days) in the drug group were significantly better than in the placebo group with 25 patients with pain, 219 pain events and 8.8 days mean pain duration. Hematocrit, red cell count, hemoglobin and platelet aggregation showed slight but significant positive changes with no corresponding alteration with placebo. The over all assessment of the therapeutic response showed 21 clearly improved patients with pentoxifylline compared to 10 such patients with placebo (p less than 0.05). Two patients on pentoxifylline and four on placebo experienced transient side effects of nausea and gastric intolerance.
 ...
PMID:Placebo controlled double-blind study of pentoxifylline in sickle cell disease patients. 333 62

In previous studies, we have shown that in the hemoocclusive crisis of sickle cell disease, red blood cells (RBC) develop reversible membrane changes which may represent a thrombogenic surface for platelets. As a result there is platelet activation and platelet derived procoagulant activity. Platelet activation is also enhanced when platelets come into contact with stored RBC in comparison with freshly obtained red blood cells from normal individuals. Pentoxifylline (P, Trental), a trisubstituted xanthine derivative, acts on the red cell membrane and decreases its effect on platelet activation. In addition, it may have direct platelet aggregation inhibitory effects. By decreasing red cell "stiffness", it may also increase the circulating life span of stored red blood cells. It is suggested that pentoxifylline may be explored as an additive in the preservation of RBC.
 ...
PMID:Influence of cold storage altered red cell surface on the function of platelets. 776 73